Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Current Deferred Revenue: 2012-2014

Historic Current Deferred Revenue for Enanta Pharmaceuticals (ENTA) over the last 1 years, with Mar 2014 value amounting to $51,000.

  • Enanta Pharmaceuticals' Current Deferred Revenue fell 55.65% to $51,000 in Q1 2014 from the same period last year, while for Mar 2014 it was $51,000, marking a year-over-year decrease of 55.65%. This contributed to the annual value of $10,000 for FY2013, which is 41.18% down from last year.
  • According to the latest figures from Q1 2014, Enanta Pharmaceuticals' Current Deferred Revenue is $51,000, which was up 920.00% from $5,000 recorded in Q4 2013.
  • Enanta Pharmaceuticals' 5-year Current Deferred Revenue high stood at $115,000 for Q1 2013, and its period low was $5,000 during Q4 2013.
  • Moreover, its 3-year median value for Current Deferred Revenue was $17,000 (2012), whereas its average is $39,600.
  • Data for Enanta Pharmaceuticals' Current Deferred Revenue shows a maximum YoY tumbled of 55.65% (in 2014) over the last 5 years.
  • Enanta Pharmaceuticals' Current Deferred Revenue (Quarterly) stood at $17,000 in 2012, then slumped by 41.18% to $5,000 in 2013, then plummeted by 55.65% to $51,000 in 2014.
  • Its Current Deferred Revenue was $51,000 in Q1 2014, compared to $5,000 in Q4 2013 and $10,000 in Q3 2013.